#GRAL↓

GRAL/ 11/12/2025 · 8:47 AM

Guggenheim Upgrades Grail to Buy with $100 Target on Galleri’s Market Leadership

Guggenheim upgrades Grail to Buy with a $100 price target, citing Galleri’s strong market position in multi-cancer early detection (MCED) despite ongoing regulatory and reimbursement challenges.

GRAL/ 10/20/2025 · 7:56 AM

Galleri Blood Test Detects 7X More Cancers | GRAIL PATHFINDER 2 Results

GRAIL's Galleri blood test increases cancer detection by over 7-fold when added to routine screenings, catching more than 50 cancer types early when most treatable. PATHFINDER 2 study shows breakthrough results.